Tech
Will any AI model reach ___ Overall Arena Score by September 30?
1510100.0%
1520100.0%
15304.5%
+2 more outcomes
TechEli LillyGLP
FDA approves Retatrutide this year?
PROBABILITY HISTORY
Market odds
Top 5 by volume
Loading market history…
OUTCOMES
Current probabilities
Market details
- Resolution status
- Open
- Platform
- Polymarket
- Close date
- Dec 31, 2026 07:00
- Display type
- binary
- Source rules
- Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
What are the current odds for FDA approves Retatrutide this year??
The current leading outcome is FDA approves Retatrutide this year? at approximately 2.5%. Probabilities can change as the market updates.
When does this prediction market close?
The currently recorded end time is Dec 31, 2026 07:00. Always check the official Polymarket page for the latest market status.
Where can I trade this market?
This website provides prediction-market data and research only. Use the Polymarket button on this page to view the original market.
Related prediction markets
⚠ Prediction markets involve substantial risk and may be restricted in your jurisdiction. Odds can change rapidly. This page is informational only; this website does not execute trades or hold user funds.